Thursday, April 23, 2020 7:05:09 PM
Antibody testing is imperfect.
But it potentially has some value for population screening and identifying levels of immunity. And it will work in blood.
For current infection and infectivity, PCR swabs from the upper respiratory tracts is the only thing that works reliably at present.
DECN at present have mothing that can or ever will compete with that.
So a labelled immunoassay approach would be the best approach for a company like DECN to take (and to have taken).
But they are late to the party and behind the herd, as ever!
DECN do not have an antibody test, or even an established methodology ready to roll.
Others do.
And this is not a diagnostic area where DECNs historical expertise is established.
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM